Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.07 AUD
Change Today +0.005 / 8.33%
Volume 195.9K
As of 12:23 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

tissue therapies ltd (TIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/15/14 - A$0.46
52 Week Low
06/11/15 - A$0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TISSUE THERAPIES LTD (TIS)

Related News

No related news articles were found.

tissue therapies ltd (TIS) Related Businessweek News

No Related Businessweek News Found

tissue therapies ltd (TIS) Details

Tissue Therapies Limited, a biomedical technology company, researches, develops, and commercializes biomedical technologies for chronic wound healing and tissue regeneration worldwide. The company commercializes VitroGro ECM, a biomimetic scaffold comprising a synthetic extracellular matrix protein that replaces the degraded matrix of a hard to heal wounds for the patients and the healthcare providers. It develops treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns, as well as treatments for psoriasis, scar prevention, and various cancers, such as breast, colon, and prostate. Tissue Therapies Limited is headquartered in Brisbane, Australia.

tissue therapies ltd (TIS) Top Compensated Officers

Chief Financial Officer and Company Secretary
Total Annual Compensation: A$174.4K
Compensation as of Fiscal Year 2014.

tissue therapies ltd (TIS) Key Developments

Professor Zee Upton to Leave Long Term Role as Consulting Chief Scientific Officer of Tissue Therapies Effective June 30, 2015

Tissue Therapies announced that Professor Zee Upton will leave her long term role as Consulting Chief Scientific Officer effective June 30, 2015 in order to take up the position of Research Director at the Institute of Medical Biology in A STAR in Singapore. TIS is currently putting in place a new arrangement with Professor Upton whereby she will advise the board on scientific matters. The contract research services provided by QUT has been essential in TIS achieving clearance in the pre-clinical area with both the EMA and the US FDA.

Tissue Therapies Announces Resignation of Roger Clarke from the Board, Effective from May 31, 2015

Tissue Therapies announced that its long term chairman, Roger Clarke, will resign from the Board on 31st May 2015.

Tissue Therapies Limited Announces Management Changes

The Board of Tissue Therapies Limited announced that the company's CEO, Dr. Steven Mercer, has resigned from the company effective as of April 7, 2015. The Board has appointed Mr. Nigel Johnson, the current Operations Director as acting CEO. Mr. Johnson has been involved in key roles within Tissue Therapies for over 10 years and has a thorough knowledge of the challenges facing Tissue Therapies in its planning for both European and US approval for its lead product VitroGro ECM. The Board will immediately commence an extensive CEO recruitment process. Once a CEO has been appointed, Mr. Johnson will resume his role as Operations Director. The current Chairman, Mr. Roger Clarke has announced that he will stand down as Chairman, and will continue in the role of non-executive Director on the Board in the short-term. The Board has appointed Dr. Cherrell Hirst as interim Chairman who, working with the other Directors, will lead the search for a CEO and a new Chairman.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TIS:AU A$0.07 AUD +0.005

TIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TIS.
View Industry Companies

Industry Analysis


Industry Average

Valuation TIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TISSUE THERAPIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at